{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T17:51:37Z","timestamp":1793901097653,"version":"4.8.0"},"reference-count":98,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Ann Plast Surg"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Glucagon-like peptide-1 (GLP-1) agonists, such as exenatide, liraglutide, dulaglutide, semaglutide, and tirzepatide, effectively manage type 2 diabetes by promoting insulin release, suppressing glucagon secretion, and enhancing glucose metabolism. They also aid weight reduction and cardiovascular health, potentially broadening their therapeutic scope. In plastic surgery, they hold promise for perioperative weight management and glycemic control, potentially impacting surgical outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A comprehensive review was conducted to assess GLP-1 agonists' utilization in plastic surgery. We analyzed relevant studies, meta-analyses, and trials to evaluate their benefits and limitations across surgical contexts, focusing on weight reduction, glycemic control, cardiovascular risk factors, and potential complications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Studies demonstrate GLP-1 agonists' versatility, spanning weight management, cardiovascular health, neurological disorders, and metabolic dysfunction-associated liver diseases. Comparative analyses highlight variations in glycemic control, weight loss, and cardiometabolic risk. Meta-analyses reveal significant reductions in hemoglobin A1C levels, especially with high-dose semaglutide (2 mg) and tirzepatide (15 mg). However, increased dosing may lead to gastrointestinal side effects and serious complications like pancreatitis and bowel obstruction. Notably, GLP-1 agonists' efficacy in weight reduction and glycemic control may impact perioperative management in plastic surgery, potentially expanding surgical candidacy for procedures like autologous flap-based breast reconstruction and influencing outcomes related to lymphedema. Concerns persist regarding venous thromboembolism and delayed gastric emptying, necessitating further investigation into bleeding and aspiration risk with anesthesia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>GLP-1 agonists offer advantages in perioperative weight management and glycemic control in plastic surgery patients. They may broaden surgical candidacy and mitigate lymphedema risk but require careful consideration of complications, particularly perioperative aspiration risk. Future research should focus on their specific impacts on surgical outcomes to optimize their integration into perioperative protocols effectively. Despite challenges, GLP-1 agonists promise to enhance surgical outcomes and patient care in plastic surgery.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/sap.0000000000004089","type":"journal-article","created":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T17:00:17Z","timestamp":1726678817000},"page":"121-127","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":23,"title":["Glucagon-Like Peptide-1 Agonists"],"prefix":"10.1097","volume":"94","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0063-8584","authenticated-orcid":false,"given":"Eloise W.","family":"Stanton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artur","family":"Manasyan","sequence":"additional","affiliation":[{"name":"Keck School of Medicine, University of Southern California, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakhi","family":"Banerjee","sequence":"additional","affiliation":[{"name":"Keck School of Medicine, University of Southern California, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"Hong","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine, Keck School of Medicine of USC, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Koesters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Daar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,9,4]]},"reference":[{"key":"bib1-20241212","doi-asserted-by":"crossref","first-page":"2042018821997320","DOI":"10.1177\/2042018821997320","article-title":"GLP-1 receptor agonists: an updated review of head-to-head clinical studies","volume":"12","year":"2021","journal-title":"Ther Adv Endocrinol Metab"},{"key":"bib3-20241212","doi-asserted-by":"crossref","first-page":"101102","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art","volume":"46","year":"2021","journal-title":"Mol Metab"},{"key":"bib4-20241212","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1080\/00325481.2015.1090295","article-title":"User's guide to mechanism of action and clinical use of GLP-1 receptor agonists","volume":"127","year":"2015","journal-title":"Postgrad Med"},{"key":"bib5-20241212","doi-asserted-by":"crossref","first-page":"e061807","DOI":"10.1136\/bmjopen-2022-061807","article-title":"Efficacy and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in overweight\/obese patients with or without diabetes mellitus: a systematic review and network meta-analysis","volume":"13","year":"2023","journal-title":"BMJ Open"},{"key":"bib6-20241212","doi-asserted-by":"crossref","first-page":"d7771","DOI":"10.1136\/bmj.d7771","article-title":"Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials","volume":"344","year":"2012","journal-title":"BMJ"},{"key":"bib7-20241212","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s12325-022-02394-w","article-title":"GLP-1 agonists for weight loss: pharmacology and clinical implications","volume":"40","year":"2023","journal-title":"Adv Ther"},{"key":"bib8-20241212","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1007\/s12325-021-01710-0","article-title":"Weight loss and maintenance related to the mechanism of action of glucagon-like peptide 1 receptor agonists","volume":"38","year":"2021","journal-title":"Adv Ther"},{"key":"bib9-20241212","first-page":"T1","article-title":"Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS","volume":"221","year":"2014","journal-title":"J Endocrinol"},{"key":"bib10-20241212","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/978-3-642-24716-3_8","article-title":"Anorexigenic effects of GLP-1 and its analogues","volume":"209","year":"2012","journal-title":"Handb Exp Pharmacol"},{"key":"bib11-20241212","doi-asserted-by":"crossref","first-page":"100456","DOI":"10.1016\/j.obmed.2022.100456","article-title":"Effects of GLP-1 agonists on proportion of weight loss in obesity with or without diabetes: systematic review and meta-analysis","volume":"35","year":"2022","journal-title":"Obesity Medicine"},{"key":"bib12-20241212","doi-asserted-by":"crossref","first-page":"e13435","DOI":"10.1111\/obr.13435","article-title":"Effect of glucagon-like peptide-1 receptor agonists on body weight in adults with obesity without diabetes mellitus-a systematic review and meta-analysis of randomized control trials","volume":"23","year":"2022","journal-title":"Obes Rev"},{"key":"bib13-20241212","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s13300-018-0536-8","article-title":"Reasonable glycemic control would help wound healing during the treatment of diabetic foot ulcers","volume":"10","year":"2019","journal-title":"Diabetes Ther"},{"key":"bib14-20241212","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1136\/bmj.332.7543.710","article-title":"Reconstructive surgery","volume":"332","year":"2006","journal-title":"BMJ"},{"key":"bib15-20241212","doi-asserted-by":"crossref","first-page":"199e","DOI":"10.1097\/01.prs.0000437224.02985.f9","article-title":"Wound healing: part I. Basic science","volume":"133","year":"2014","journal-title":"Plast Reconstr Surg"},{"key":"bib16-20241212","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1136\/postgradmedj-2019-137186","article-title":"An overview of GLP-1 agonists and recent cardiovascular outcomes trials","volume":"96","year":"2020","journal-title":"Postgrad Med J"},{"key":"bib17-20241212","article-title":"Glucagon-like peptide-1 agonists: what the orthopaedic surgeon needs to know","volume":"12","year":"2024","journal-title":"JBJS Rev"},{"key":"bib18-20241212","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.peptides.2017.11.021","article-title":"Glucose-dependent insulinotropic polypeptide (GIP) receptor antagonists as anti-diabetic agents","volume":"100","year":"2018","journal-title":"Peptides"},{"issue":"Spec Feature","key":"bib21-20241212","first-page":"131","article-title":"Trulicity (dulaglutide): a new GLP-1 receptor agonist once-weekly subcutaneous injection approved for the treatment of patients with type 2 diabetes","volume":"8","year":"2015","journal-title":"Am Health Drug Benefits"},{"key":"bib25-20241212","first-page":"e076410","article-title":"Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis","volume":"384","year":"2024","journal-title":"BMJ"},{"key":"bib26-20241212","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJMoa2302392","article-title":"Daily Oral GLP-1 receptor agonist orforglipron for adults with obesity","volume":"389","year":"2023","journal-title":"N Engl J Med"},{"key":"bib27-20241212","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/S0140-6736(23)01163-7","article-title":"Efficacy and safety of co-administered once-weekly cagrilintide 2\u00b74 mg with once-weekly semaglutide 2\u00b74 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial","volume":"402","year":"2023","journal-title":"Lancet"},{"key":"bib28-20241212","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple-hormone-receptor agonist retatrutide for obesity - a phase 2 trial","volume":"389","year":"2023","journal-title":"N Engl J Med"},{"key":"bib29-20241212","doi-asserted-by":"crossref","first-page":"e2695","DOI":"10.1210\/clinem\/dgaa285","article-title":"Obesity, polycystic ovary syndrome, and infertility: a new avenue for GLP-1 receptor agonists","volume":"105","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"bib30-20241212","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1210\/jc.2008-0115","article-title":"Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome","volume":"93","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"bib31-20241212","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.tice.2015.12.003","article-title":"Sex steroid receptors and apoptosis-related proteins are differentially expressed in polycystic ovaries of adult dogs","volume":"48","year":"2016","journal-title":"Tissue Cell"},{"key":"bib32-20241212","first-page":"127","article-title":"MicroRNA-183-96-182 cluster regulates bovine granulosa cell proliferation and cell cycle transition by coordinately targeting FOXO1","volume":"94","year":"2016","journal-title":"Biol Reprod"},{"key":"bib33-20241212","first-page":"1484321","article-title":"GLP-1\/GLP-1R signaling regulates ovarian PCOS-associated granulosa cells proliferation and antiapoptosis by modification of forkhead box protein O1 phosphorylation sites","volume":"2020","year":"2020","journal-title":"Int J Endocrinol"},{"key":"bib34-20241212","doi-asserted-by":"crossref","first-page":"118731","DOI":"10.1016\/j.lfs.2020.118731","article-title":"Liraglutide mends cognitive impairment by averting notch signaling pathway overexpression in a rat model of polycystic ovary syndrome","volume":"265","year":"2021","journal-title":"Life Sci"},{"key":"bib35-20241212","doi-asserted-by":"crossref","first-page":"2042018821989238","DOI":"10.1177\/2042018821989238","article-title":"The potential role of incretin-based therapies for polycystic ovary syndrome: a narrative review of the current evidence","volume":"12","year":"2021","journal-title":"Ther Adv Endocrinol Metab"},{"key":"bib36-20241212","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.3390\/ijms20051050","article-title":"Liraglutide and its neuroprotective properties-focus on possible biochemical mechanisms in Alzheimer's disease and cerebral ischemic events","volume":"20","year":"2019","journal-title":"Int J Mol Sci"},{"key":"bib37-20241212","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/362075a0","article-title":"Alzheimer amyloid protein precursor complexes with brain GTP-binding protein G(o)","volume":"362","year":"1993","journal-title":"Nature"},{"key":"bib38-20241212","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1046\/j.1471-4159.2003.02073.x","article-title":"Glucagon-like peptide 1 modulates calcium responses to glutamate and membrane depolarization in hippocampal neurons","volume":"87","year":"2003","journal-title":"J Neurochem"},{"key":"bib39-20241212","first-page":"CD012990","article-title":"GLP-1 receptor agonists for Parkinson's disease","volume":"7","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"bib40-20241212","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/jnr.21483","article-title":"Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease","volume":"86","year":"2008","journal-title":"J Neurosci Res"},{"key":"bib41-20241212","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/jcbfm.2015.17","article-title":"Glucagon-like receptor 1 agonists and DPP-4 inhibitors: potential therapies for the treatment of stroke","volume":"35","year":"2015","journal-title":"J Cereb Blood Flow Metab"},{"key":"bib42-20241212","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.4103\/1673-5374.272620","article-title":"Exendin-4 attenuates pain-induced cognitive impairment by alleviating hippocampal neuroinflammation in a rat model of spinal nerve ligation","volume":"15","year":"2020","journal-title":"Neural Regeneration Res"},{"key":"bib43-20241212","doi-asserted-by":"crossref","first-page":"11701","DOI":"10.1523\/JNEUROSCI.1799-17.2017","article-title":"Autocrine Interleukin-10 mediates glucagon-like peptide-1 receptor-induced spinal microglial \u03b2-endorphin expression","volume":"37","year":"2017","journal-title":"J Neurosci"},{"key":"bib44-20241212","doi-asserted-by":"crossref","first-page":"721135","DOI":"10.3389\/fendo.2021.721135","article-title":"GLP-1 receptor agonists: beyond their pancreatic effects","volume":"12","year":"2021","journal-title":"Front Endocrinol"},{"key":"bib45-20241212","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jneuroim.2017.12.005","article-title":"Both classic Gs-cAMP\/PKA\/CREB and alternative Gs-cAMP\/PKA\/p38\u03b2\/CREB signal pathways mediate exenatide-stimulated expression of M2 microglial markers","volume":"316","year":"2018","journal-title":"J Neuroimmunol"},{"key":"bib46-20241212","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1748-1716.2010.02150.x","article-title":"GLP-1 playing the role of a gut regulatory compound","volume":"201","year":"2011","journal-title":"Acta Physiol"},{"key":"bib47-20241212","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/jgh.13808","article-title":"Glucagon-like peptide-1 analog, liraglutide, improves visceral sensation and gut permeability in rats","volume":"33","year":"2018","journal-title":"J Gastroenterol Hepatol"},{"key":"bib48-20241212","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.peptides.2018.09.002","article-title":"Glucagon-like peptide-1 receptor action in the vasculature","volume":"111","year":"2019","journal-title":"Peptides"},{"key":"bib49-20241212","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/aps.2011.149","article-title":"Glucagon-like peptide-1 activates endothelial nitric oxide synthase in human umbilical vein endothelial cells","volume":"33","year":"2012","journal-title":"Acta Pharmacol Sin"},{"key":"bib50-20241212","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jcjd.2019.09.003","article-title":"Mechanisms by which glucagon-like-peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors reduce cardiovascular risk in adults with type 2 diabetes mellitus","volume":"44","year":"2020","journal-title":"Can J Diabetes"},{"key":"bib51-20241212","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.bbrc.2010.12.131","article-title":"Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces intimal thickening after vascular injury","volume":"405","year":"2011","journal-title":"Biochem Biophys Res Commun"},{"key":"bib52-20241212","doi-asserted-by":"crossref","first-page":"120944","DOI":"10.1016\/j.biomaterials.2021.120944","article-title":"Effective oral delivery of Exenatide-Zn2+ complex through distal ileum-targeted double layers nanocarriers modified with deoxycholic acid and glycocholic acid in diabetes therapy","volume":"275","year":"2021","journal-title":"Biomaterials"},{"key":"bib53-20241212","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1177\/1479164111404257","article-title":"A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE\u2212\/\u2212 mouse model","volume":"8","year":"2011","journal-title":"Diab Vasc Dis Res"},{"key":"bib54-20241212","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1161\/CIRCULATIONAHA.122.059595","article-title":"GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes","volume":"146","year":"2022","journal-title":"Circulation"},{"key":"bib55-20241212","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.diabres.2018.10.013","article-title":"Glucagon-like peptide-1 analogue liraglutide facilitates wound healing by activating PI3K\/Akt pathway in keratinocytes","volume":"146","year":"2018","journal-title":"Diabetes Res Clin Pract"},{"key":"bib56-20241212","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jss.2016.09.024","article-title":"Exendin-4, a glucagon-like peptide-1 analogue, accelerates diabetic wound healing","volume":"208","year":"2017","journal-title":"J Surg Res"},{"issue":"3\u20134","key":"bib57-20241212","first-page":"202","article-title":"Adverse effects of GLP-1 receptor agonists","volume":"11","year":"2014","journal-title":"Rev Diabet Stud"},{"key":"bib58-20241212","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1001\/jama.2023.19574","article-title":"Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss","volume":"330","year":"2023","journal-title":"JAMA"},{"key":"bib59-20241212","doi-asserted-by":"crossref","first-page":"102427","DOI":"10.1016\/j.dsx.2022.102427","article-title":"Adverse drug reactions of GLP-1 agonists: a systematic review of case reports","volume":"16","year":"2022","journal-title":"Diabetes Metab Syndr"},{"key":"bib60-20241212","doi-asserted-by":"crossref","first-page":"g2366","DOI":"10.1136\/bmj.g2366","article-title":"Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies","volume":"348","year":"2014","journal-title":"BMJ"},{"key":"bib61-20241212","first-page":"e230257","article-title":"Glucagon-like peptide 1 receptor agonists and thyroid cancer: is it the time to be concerned?","volume":"12","year":"2023","journal-title":"Endocr Connect"},{"key":"bib62-20241212","doi-asserted-by":"crossref","first-page":"e001986","DOI":"10.1136\/bmjopen-2012-001986","volume":"3","year":"2013","journal-title":"BMJ Open"},{"key":"bib63-20241212","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.eprac.2023.11.007","article-title":"Efficacy and safety of glucagon-like peptide-1 receptor agonists on body weight and cardiometabolic parameters in individuals with obesity and without diabetes: a systematic review and meta-analysis","volume":"30","year":"2024","journal-title":"Endocr Pract"},{"key":"bib64-20241212","doi-asserted-by":"crossref","first-page":"765","DOI":"10.2337\/dc20-1473","article-title":"Efficacy and safety of dulaglutide 3.0 mg and 4.5 mg versus dulaglutide 1.5 mg in metformin-treated patients with type 2 diabetes in a randomized controlled trial (AWARD-11)","volume":"44","year":"2021","journal-title":"Diabetes Care"},{"key":"bib65-20241212","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","article-title":"Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial","volume":"5","year":"2017","journal-title":"Lancet Diabet Endocrinol"},{"key":"bib66-20241212","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/ijo.2013.120","article-title":"Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE maintenance randomized study","volume":"37","year":"2013","journal-title":"Int J Obes (Lond)"},{"key":"bib67-20241212","doi-asserted-by":"crossref","first-page":"101076","DOI":"10.1016\/j.artd.2022.101076","article-title":"Dexamethasone is associated with a statistically significant increase in postoperative blood glucose levels following primary total knee arthroplasty","volume":"19","year":"2023","journal-title":"Arthroplast Today"},{"key":"bib68-20241212","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.2106\/JBJS.17.01316","article-title":"Postoperative blood glucose levels predict infection after total joint arthroplasty","volume":"100","year":"2018","journal-title":"J Bone Joint Surg Am"},{"key":"bib69-20241212","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1053\/j.jvca.2013.06.021","article-title":"Intravenous GLP-1 (7-36) amide for prevention of hyperglycemia during cardiac surgery: a randomized, double-blind, placebo-controlled study","volume":"28","year":"2014","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"bib70-20241212","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1111\/dom.13029","article-title":"Effect of continuous exenatide infusion on cardiac function and peri-operative glucose control in patients undergoing cardiac surgery: a single-blind, randomized controlled trial","volume":"19","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"bib71-20241212","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.amjcard.2007.05.022","article-title":"Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting","volume":"100","year":"2007","journal-title":"Am J Cardiol"},{"key":"bib72-20241212","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1001\/jama.2019.2941","article-title":"The future of the GLP-1 receptor agonists","volume":"321","year":"2019","journal-title":"JAMA"},{"key":"bib73-20241212","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1007\/s11154-021-09669-7","article-title":"Lessons from bariatric surgery: can increased GLP-1 enhance vascular repair during cardiometabolic-based chronic disease?","volume":"22","year":"2021","journal-title":"Rev Endocr Metab Disord"},{"key":"bib74-20241212","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.arth.2023.12.014","article-title":"Semaglutide and other GLP-1 agonists: a boon for the arthroplasty industry?","volume":"39","year":"2024","journal-title":"J Arthroplasty"},{"key":"bib75-20241212","first-page":"244","article-title":"The effect of body mass index on outcome of abdominoplasty operations","volume":"5","year":"2016","journal-title":"World J Plast Surg"},{"key":"bib76-20241212","first-page":"727","article-title":"Impact of age, body mass index, and resection weight on postoperative complications in reduction mammaplasty","volume":"151","year":"2023","journal-title":"Plast Reconstr Surg"},{"key":"bib77-20241212","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1055\/s-0041-1727202","article-title":"Stratification of surgical risk in DIEP breast reconstruction based on classification of obesity","volume":"38","year":"2022","journal-title":"J Reconstr Microsurg"},{"key":"bib78-20241212","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/j.bjps.2020.12.043","article-title":"Impact of body mass index on free DIEP flap breast reconstruction: a multicenter cohort study","volume":"74","year":"2021","journal-title":"J Plast Reconstr Aesthet Surg"},{"key":"bib79-20241212","doi-asserted-by":"crossref","first-page":"101351","DOI":"10.1016\/j.molmet.2021.101351","article-title":"GLP-1 physiology informs the pharmacotherapy of obesity","volume":"57","year":"2022","journal-title":"Mol Metab"},{"key":"bib80-20241212","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.bjps.2018.03.003","article-title":"A retrospective investigation of abdominal visceral fat, body mass index (BMI), and active smoking as risk factors for donor site wound healing complications after free DIEP flap breast reconstructions","volume":"71","year":"2018","journal-title":"J Plast Reconstr Aesthet Surg"},{"key":"bib81-20241212","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","year":"2021","journal-title":"N Engl J Med"},{"key":"bib82-20241212","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2\u00b74 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","year":"2021","journal-title":"Lancet"},{"key":"bib83-20241212","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1001\/jama.2021.1831","article-title":"Effect of subcutaneous Semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial","volume":"325","year":"2021","journal-title":"JAMA"},{"key":"bib84-20241212","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial","volume":"325","year":"2021","journal-title":"JAMA"},{"key":"bib85-20241212","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1007\/s00266-023-03508-7","article-title":"Literature review: venous thromboembolism prophylaxis in plastic surgery","volume":"47","year":"2023","journal-title":"Aesthetic Plast Surg"},{"key":"bib86-20241212","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.2147\/DDDT.S312347","article-title":"Effects of exenatide on coagulation and platelet aggregation in patients with type 2 diabetes","volume":"15","year":"2021","journal-title":"Drug Des Devel Ther"},{"key":"bib87-20241212","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.cmet.2016.06.009","article-title":"The cardiovascular biology of glucagon-like peptide-1","volume":"24","year":"2016","journal-title":"Cell Metab"},{"key":"bib88-20241212","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12902-015-0005-6","article-title":"The effects of treatment with liraglutide on atherothrombotic risk in obese young women with polycystic ovary syndrome and controls","volume":"15","year":"2015","journal-title":"BMC Endocr Disord"},{"key":"bib89-20241212","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/MCA.0000000000000830","article-title":"Effect of semaglutide on coronary atherosclerosis progression in patients with type II diabetes: rationale and design of the semaglutide treatment on coronary progression trial","volume":"31","year":"2020","journal-title":"Coron Artery Dis"},{"key":"bib90-20241212","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3389\/fendo.2019.00155","article-title":"The discovery and development of liraglutide and semaglutide","volume":"10","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"bib91-20241212","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.7150\/ijbs.59965","article-title":"GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential","volume":"17","year":"2021","journal-title":"Int J Biol Sci"},{"key":"bib93-20241212","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1056\/NEJMc1201684","article-title":"Lower-extremity lymphedema and elevated body-mass index","volume":"366","year":"2012","journal-title":"N Engl J Med"},{"key":"bib94-20241212","doi-asserted-by":"crossref","first-page":"379","DOI":"10.21037\/gs.2017.11.04","article-title":"Breast cancer-related lymphedema: risk factors, precautionary measures, and treatments","volume":"7","year":"2018","journal-title":"Gland Surg"},{"key":"bib95-20241212","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1245\/s10434-008-0270-y","article-title":"Lymphedema microsurgical preventive healing approach: a new technique for primary prevention of arm lymphedema after mastectomy","volume":"16","year":"2009","journal-title":"Ann Surg Oncol"},{"key":"bib96-20241212","doi-asserted-by":"crossref","first-page":"1099403","DOI":"10.3389\/fphys.2023.1099403","article-title":"Mapping the lymphatic system across body scales and expertise domains: a report from the 2021 National Heart, Lung, and Blood Institute workshop at the Boston Lymphatic Symposium","volume":"14","year":"2023","journal-title":"Front Physiol"},{"key":"bib97-20241212","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1089\/lrb.2022.0003","article-title":"Adipose tissue in lymphedema: a central feature of pathology and target for pharmacologic therapy","volume":"21","year":"2023","journal-title":"Lymphat Res Biol"},{"key":"bib98-20241212","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1007\/s00520-023-07721-7","article-title":"Body mass index increases the risk of breast cancer-related lymphedema at 6-18 months after surgery: a retrospective study","volume":"31","year":"2023","journal-title":"Support Care Cancer"},{"key":"bib99-20241212","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1089\/lrb.2019.0009","article-title":"Body mass index as a major risk factor for severe breast cancer-related lymphedema","volume":"18","year":"2020","journal-title":"Lymphat Res Biol"},{"key":"bib100-20241212","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1097\/PRS.0000000000001271","article-title":"Obesity-induced lymphedema: clinical and lymphoscintigraphic features","volume":"135","year":"2015","journal-title":"Plast Reconstr Surg"},{"key":"bib101-20241212","doi-asserted-by":"crossref","first-page":"C375","DOI":"10.1152\/ajpcell.00379.2020","article-title":"Adipose tissue inflammation and metabolic dysfunction in obesity","volume":"320","year":"2021","journal-title":"Am J Physiol Cell Physiol"},{"key":"bib102-20241212","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/PRS.0000000000007021","article-title":"Body mass index and lymphedema morbidity: comparison of obese versus normal-weight patients","volume":"146","year":"2020","journal-title":"Plast Reconstr Surg"},{"key":"bib103-20241212","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s12933-023-01897-2","article-title":"The use of sodium-glucose co-transporter-2 inhibitors or glucagon-like peptide-1 receptor agonists versus sulfonylureas and the risk of lower limb amputations: a nation-wide cohort study","volume":"22","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"bib104-20241212","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s12871-019-0848-x","article-title":"Point-of-care ultrasound defines gastric content in elective surgical patients with type 2 diabetes mellitus: a prospective cohort study","volume":"19","year":"2019","journal-title":"BMC Anesthesiol"},{"key":"bib105-20241212","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/EJA.0000000000001914","article-title":"Glucagon-like peptide-1 receptor agonists in the perioperative period: implications for the anaesthesiologist","volume":"41","year":"2024","journal-title":"Eur J Anaesthesiol"}],"container-title":["Annals of Plastic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/SAP.0000000000004089","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T08:02:46Z","timestamp":1733990566000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/SAP.0000000000004089"}},"subtitle":["A Practical Overview for Plastic and Reconstructive Surgeons"],"short-title":[],"issued":{"date-parts":[[2024,9,4]]},"references-count":98,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/sap.0000000000004089","relation":{},"ISSN":["1536-3708","0148-7043"],"issn-type":[{"value":"1536-3708","type":"electronic"},{"value":"0148-7043","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,4]]}}}